Skip to main navigation
Skip to search
Skip to main content
University of Dundee Discovery Portal Home
Search content at University of Dundee Discovery Portal
Home
Profiles
Research units
Research Outputs
Projects
Datasets
Theses
Activity
Press/Media
Research Facilities
Prizes
Medical management of critical limb ischaemia: where do we stand today?
M. A. Lambert
,
J. J. F. Belch
Research output
:
Contribution to journal
›
Article
›
peer-review
52
Link opens in a new tab
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Medical management of critical limb ischaemia: where do we stand today?'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Acute Limb Ischemia
16%
Allreduce
16%
Angiogenic Growth Factors
16%
Anticoagulation
16%
Antiplatelet Agents
16%
Arterial Occlusion
16%
Aspirin
16%
Cardiovascular Risk
16%
Cardiovascular Risk Factors
16%
Cilostazol
16%
Clopidogrel
16%
Critical Limb Ischemia
100%
Death from Cardiovascular Diseases
16%
Diabetes Management
16%
Disease Progression
16%
Endovascular Procedures
16%
Follow-up Data
16%
Heparin
16%
Hyperbaric Oxygen
16%
Hypertension Management
16%
Iloprost
16%
Incidence of Cardiovascular Events
16%
Ischemic Pain
16%
Lack of Evidence
16%
Limb Loss
16%
Major Amputation
16%
Medical Management
100%
Mortality Rate
16%
Myocardial Infarction Stroke
16%
Naftidrofuryl
16%
Pentoxifylline
16%
Peripheral Arterial Disease
33%
Phase I Study
16%
Prostanoids
16%
Quality of Life
16%
Randomized Controlled Trial
33%
Rest Pain
16%
Risk Reduction
16%
Severe Disease
16%
Smoke Treatment
16%
Smoking Cessation
16%
Stem Cells
16%
Surgical Intervention
16%
Thrombolysis
16%
Ulcer
16%
Ulcer Healing
16%
Warfarin
16%
Medicine and Dentistry
Acetylsalicylic Acid
14%
Amputation
14%
Anticoagulation
14%
Antiplatelet Drug
14%
Apoplexy
14%
Arteriosclerosis Obliterans
28%
Artery Occlusion
14%
Blood Clot Lysis
14%
Cardiovascular Disease
14%
Cardiovascular Risk
14%
Cardiovascular System
14%
Cilostazol
14%
Clopidogrel
14%
Critical Limb Ischemia
100%
Diabetes
14%
Disease Exacerbation
14%
Growth Factor
14%
Heparin
14%
Hyperbaric Medicine
14%
Hyperlipidemia
14%
Hypertension
14%
Iloprost
14%
Limb
42%
Mortality Rate
14%
Myocardial Infarction
14%
Naftidrofuryl
14%
Nicotine Withdrawal
14%
Pentoxifylline
14%
Prostaglandin
14%
Quality of Life
14%
Randomized Controlled Trial
28%
Rest Pain
14%
Stem Cell
14%
Ulcer
14%
Ulcer Healing
14%
Warfarin
14%
Nursing and Health Professions
Amputation
14%
Anticoagulation
14%
Antithrombocytic Agent
14%
Artery Occlusion
14%
Cardiovascular Disease
14%
Cardiovascular Risk
14%
Cardiovascular System
14%
Cerebrovascular Accident
14%
Cilostazol
14%
Clopidogrel
14%
Critical Limb Ischemia
100%
Disease Exacerbation
14%
Disease Management
100%
Efficacy
28%
Growth Factor
14%
Heart Infarction
14%
Heparin
14%
Hyperbaric Medicine
14%
Hyperlipidemia
14%
Hypertension
14%
Iloprost
14%
Mortality Rate
14%
Naftidrofuryl
14%
Nicotine Withdrawal
14%
Pentoxifylline
14%
Peripheral Occlusive Artery Disease
28%
Prostaglandin
14%
Quality of Life
14%
Ulcer
14%
Ulcer Healing
14%
Warfarin
14%
Pharmacology, Toxicology and Pharmaceutical Science
Acetylsalicylic Acid
14%
Antithrombocytic Agent
14%
Artery Occlusion
14%
Cardiovascular Disease
14%
Cardiovascular Risk
14%
Cerebrovascular Accident
14%
Cilostazol
14%
Clopidogrel
14%
Critical Limb Ischemia
100%
Disease Exacerbation
14%
Growth Factor
14%
Heart Infarction
14%
Heparin
14%
Hyperlipidemia
14%
Hypertension
14%
Iloprost
14%
Mortality Rate
14%
Naftidrofuryl
14%
Pentoxifylline
14%
Peripheral Occlusive Artery Disease
28%
Prostaglandin
14%
Randomized Controlled Trial
28%
Ulcer
14%
Ulcer Healing
14%
Warfarin
14%
Neuroscience
Antiplatelet Drug
14%
Aspirin
14%
Cardiovascular System
42%
Cerebrovascular Accident
14%
Cilostazol
14%
Clopidogrel
14%
Growth Factor
14%
Heparin
14%
Hyperbaric Medicine
14%
Hypertension
14%
Iloprost
14%
Ischemia
100%
Myocardial Infarction
14%
Naftidrofuryl
14%
Pentoxifylline
14%
Prostaglandin
14%
Quality of Life
14%
Randomized Controlled Trial
28%
Risk Factor
14%
Stem Cell
14%
Warfarin
14%